Compare Heron Therapeutics Inc (HRTX) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs MPLX LP — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while MPLX LP trades at $56.75 (market cap $57.97B). The key difference: MPLX LP is far larger — about 633.8× Heron Therapeutics Inc's market cap, and MPLX LP pays a 7.54% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | MPLX | |
|---|---|---|
Market Cap | $91.46M | $57.97B |
Sector | Health | Technology |
52-Week High | $1.96 | $59.17 |
52-Week Low | $0.39 | $47.80 |
Enterprise Value | $189.36M | $82.60B |
Dividend Yield | — | 7.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
MPLX trades at $57.13, up 0.12% today, with a bullish technical signal from moving averages and a consensus analyst price target of $60.00. The company reported strong profitability with a 41.24% net income margin in 2025 and has beaten earnings estimates in two of the last three quarters. Recent news highlights its resilient midstream model and attractive dividend yield.
The outlook for MPLX is positive, supported by stable cash flows, a high dividend yield, and analyst optimism. Key risks include exposure to energy market volatility and a recent earnings miss. The stock offers value with a P/E of 12.35 and strong institutional buy ratings, but investors should monitor execution on growth projects and macroeconomic trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
